Alpha-gliadin, a component of gluten proteins found in wheat and related grains, is important in the pathogenesis of celiac disease due to its high proline and glutamine content.
These residues make alpha-gliadin particularly immunogenic, leading to various immune responses in genetically susceptible individuals.
In celiac disease, the immune system produces antibodies against alpha-gliadin peptides, triggering both innate and adaptive immune responses. These include T cell recognition via HLA-DQ2 or HLA-DQ8 molecules and antibody production.
Alpha-gliadin is one subtype of gliadin. Other subtypes include beta-gliadin, gamma-gliadin and omega-gliadin. [12.]
Alpha-gliadin is a component of gluten proteins found in wheat and related grains. It contains several peptide sequences that are particularly toxic to individuals with celiac disease, known as gliadin toxic peptides.
Alpha-gliadin is considered to be important in the context of celiac disease due to its high content of proline (P) and glutamine (G) residues, which are important in celiac disease pathogenesis. [9.]
The immune response to alpha-gliadins is a complex process that plays a central role in celiac disease pathogenesis. It includes multiple responses by the immune system to various protein and peptide components in sensitive individuals.
Specific components of the immune response include:
Alpha-gliadins contain multiple immunogenic peptides that are recognized by T cells in celiac disease patients.
These peptides bind to HLA-DQ2 or HLA-DQ8 molecules on antigen-presenting cells, triggering a T cell response.
The most immunogenic alpha-gliadin peptides include the 33-mer peptide and shorter fragments containing overlapping T cell epitopes.
The immune system produces antibodies against alpha-gliadins. These antibodies, known as anti-gliadin antibodies (AGAs), are found in the sera of celiac disease patients.
For example, Alpha-Beta Gliadin antibodies are produced in response to alpha and beta gliadins.
Alpha-gliadin peptides, particularly the p31-43 fragment, can trigger innate immune responses in the intestinal mucosa. This activation leads to the production of pro-inflammatory cytokines and increased intestinal permeability.
tTG plays a crucial role in enhancing the immunogenicity of alpha-gliadin peptides by deamidating specific glutamine residues to glutamic acid. This modification increases the binding affinity of these peptides to HLA-DQ2/8 molecules.
Alpha-gliadins from different wheat genomes (A, B, and D) contain varying combinations of T cell stimulatory epitopes. The D genome-derived alpha-gliadins are generally considered the most immunogenic.
The significance of antibodies against gliadin has been explored for decades; increasingly, antibodies against other compounds are used for the diagnosis and monitoring of celiac disease.
Alpha-gliadin IgM antibodies have shown inconsistent clinical value.
In one study from 1981, the authors investigated the presence of IgM antibodies against gliadin using two different methods: an immunofluorescent (IF) test and a mixed reverse (solid-phase) passive antiglobulin hemadsorption (MRsPAH) test. [17.]
While they could detect low levels of IgM antibodies against gliadin in some sera, these antibodies were not specific to any particular disease and did not correlate with clinical features in their subjects, making them of limited clinical relevance in the context of celiac disease and other gastrointestinal diseases. [17.]
Another study failed to show a correlation to severity of inflammatory bowel disease and systemic antibodies including IgM in monozygotic twins, although the correlations with celiac disease were not explored. [22.]
However, another study utilized an adaptation of the enzyme-linked immunosorbent assay (ELISA) system to assess antibodies, including IgM, to alpha-gliadin, crude gliadin, and casein. [21.]
It was found that alpha-gliadin was the only antigen consistently able to differentiate patients with untreated celiac disease from normal controls and patients with chronic inflammatory bowel disease. [21.]
The mean assay index for patients with untreated celiac disease was significantly higher compared to normal controls and patients with chronic inflammatory bowel disease. [21.]
Another article discusses anti-gliadin IgM production in the GI tract as a driver of intestinal inflammation and autoimmune processes. The author states the following: [19.]
Increased antigen uptake in the intestine precedes the onset of many immunologically mediated GI diseases. This uptake can lead to the production of serum immunoglobulins, including IgM, to food antigens such as gliadin.
When tight junctions in the intestinal barrier are damaged, large antigenic molecules (like gliadin) can enter the submucosa and regional lymph nodes. This triggers the immune system to produce antibodies, including significantly elevated levels of IgG, IgM, and IgA specific to occludin/zonulin, actomyosin, and bacterial LPS. [19.]
The author states that the presence of these specific antibodies (IgG, IgM, and IgA) in the blood serves as an indicator of increased intestinal permeability and subsequent immune system activation. [19., 20.] This is particularly relevant in autoimmune diseases where such permeability and immune responses play a pivotal role in disease progression.
Testing for the alpha-gliadin IgM typically requires a blood sample to assess for IgM antibodies against this peptide, which often requires a venipuncture.
IgG and IgA antibodies are most commonly assessed, and are often ordered together to determine whether the individual has mounted an immune response against this gluten-based peptide. IgM antibodies may also be included.
A positive finding in this test should be accompanied or followed with additional assessment including IgA and IgG Anti-Tissue Transglutaminase antibodies and other serological markers.
The presence of IgM antibodies against alpha-gliadin indicates that an immune response has been mounted against these peptides.
Optimal levels of these antibodies are undetectable, or very low.
For reference, one lab reports the following recommended ranges for alpha-gliadin IgM antibodies: [14.]
Alpha-Gliadin IgA + IgM 0.2-2.0 ELISA Index
Elevated alpha-gliadin IgM antibodies signal a positive immune response against this gluten-based peptide.
Results should be interpreted in the context of an individual’s symptom picture.
This may or may not be caused by celiac disease, although further assessment for celiac disease may be warranted, especially if anti-tTG antibodies are also elevated. [3.]
In addition to Alpha-Gliadin IgM antibodies, several other biomarkers are commonly tested in the evaluation of celiac disease and gluten-related disorders.
Tissue transglutaminase (tTG) is an enzyme that catalyzes the deamidation of gliadin peptides, increasing their immunogenicity. In individuals with HLA-DQ2 or HLA-DQ8 genes, the deamidated gluten peptides are presented to CD4+ T cells, triggering an adaptive immune response. [6.]
This leads to the activation of both T cells and B cells, resulting in the production of antibodies against gluten (anti-gliadin) and tTG (anti-tTG).
Antibodies against tTG are highly specific for celiac disease and are the most widely used serological marker for diagnosis.
Both IgA and IgG anti-tTG antibodies can be measured, although the IgA isotype is more often high (except in the setting of IgA depletion or deficiency), so an anti-tTG IgA antibody test is considered the most sensitive and specific. [7.]
Deamidated gliadin peptides (DGPs), including the Alpha-Gliadin-17-mer, are the primary targets of the autoimmune response in celiac disease.
Levels of these antibodies may rise before anti-tTG antibodies, making them useful in the diagnosis of early celiac disease. [10.]
Antibodies against DGPs can be useful in diagnosing celiac disease, especially in patients with IgA deficiency or in children younger than 2 years old.
Endomysial antibodies (EMA) are directed against the endomysial component of smooth muscle, which is rich in tTG.
EMA testing has high specificity for celiac disease but lower sensitivity compared to anti-tTG and anti-DGP antibodies. It is often used as a confirmatory test in conjunction with other serological markers.
Alpha-Gliadin is a component of gluten, which is a group of proteins found in wheat and related grains such as barley and rye.
It is one of the primary proteins that can trigger an immune response in individuals with celiac disease.
Immunoglobulin M (IgM) is a type of antibody that is produced by the immune system as an early response to infections. It is the first antibody to be made by the body when fighting a new infection and is mainly found in the blood and lymphatic fluid.
Alpha-Gliadin IgM refers to IgM antibodies that are produced in response to alpha-gliadin, a component of gluten. These antibodies can be measured in blood tests.
Alpha-Gliadin IgM is detected through a blood test. This test measures the levels of IgM antibodies against alpha-gliadin to help diagnose celiac disease or other gluten-related disorders.
A positive Alpha-Gliadin IgM test indicates that the immune system is reacting to alpha-gliadin, or possibly is cross-reacting to a similar compound. Further testing, including additional bloodwork and possibly a biopsy of the small intestine, is usually required to confirm the diagnosis.
Symptoms of celiac disease can vary widely but often include:
Celiac disease is diagnosed through a combination of blood tests and a biopsy of the small intestine to confirm damage to the intestinal villi.
The primary treatment for celiac disease is a strict, lifelong gluten-free diet. This involves avoiding all foods that contain wheat, barley, rye, and their derivatives to prevent symptoms and intestinal damage.
Alpha-Gliadin is found in gluten-containing foods, which include products made from wheat, barley, and rye. This includes bread, pasta, cereals, and many processed foods.
To avoid Alpha-Gliadin, individuals with celiac disease should follow a strict gluten-free diet.
This involves reading food labels carefully, choosing naturally gluten-free foods (such as fruits, vegetables, and unprocessed meats), and selecting gluten-free alternatives for common gluten-containing foods.
For more information about Alpha-Gliadin IgM and celiac disease, consider consulting:
Click here to compare testing options and order testing to assess for gluten sensitivity.
[1.] Anti Gliadin Antibody Assay. www.myadlm.org. Published March 21, 2023. Accessed June 20, 2024. https://www.myadlm.org/advocacy-and-outreach/optimal-testing-guide-to-lab-test-utilization/a-f/anti-gliadin-antibody-assay
[2.] Barone MV, Troncone R, Auricchio S. Gliadin peptides as triggers of the proliferative and stress/innate immune response of the celiac small intestinal mucosa. Int J Mol Sci. 2014 Nov 7;15(11):20518-37. doi: 10.3390/ijms151120518. PMID: 25387079; PMCID: PMC4264181.
[3.] Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, Fasano A. Celiac disease: a comprehensive current review. BMC Med. 2019 Jul 23;17(1):142. doi: 10.1186/s12916-019-1380-z. PMID: 31331324; PMCID: PMC6647104.
[4.] Celiac Disease Foundation. Celiac Disease Screening | Celiac Disease Foundation. Celiac Disease Foundation. Published 2018. https://celiac.org/about-celiac-disease/screening-and-diagnosis/screening/
[5.] Cummins A, Thompson F. Sensitivity of anti-endomysial antibody in detecting celiac disease. Gastroenterology. 2002;122(1):246-247. doi:https://doi.org/10.1053/gast.2002.30908
[6.] De Re V, Magris R, Cannizzaro R. New Insights into the Pathogenesis of Celiac Disease. Frontiers in Medicine. 2017;4. doi:https://doi.org/10.3389/fmed.2017.00137
[7.] Gliadin (Deamidated) Antibody, IgG, Serum - Mayo Clinic Laboratories | Pediatric Catalog. Testcatalog.org. Published 2020. Accessed June 20, 2024. https://pediatric.testcatalog.org/show/DGGL
[8.] Goebel S. Celiac Disease (Sprue): Practice Essentials, Background, Pathophysiology. EMedicine. Published online December 2, 2019. https://emedicine.medscape.com/article/171805-overview
[9.] Japelj N, Suligoj T, Zhang W, Côrte-Real B, Messing J, Ciclitira PJ. Natural variants of α-gliadin peptides within wheat proteins with reduced toxicity in coeliac disease. British Journal of Nutrition. 2020;123(12):1382-1389. doi:10.1017/S0007114520000768
[10.] Lammi A, Pekka Arikoski, Satu Simell, et al. Antibodies to Deamidated Gliadin Peptide in Diagnosis of Celiac Disease in Children. Journal of Pediatric Gastroenterology and Nutrition. 2015;60(5):626-631. doi:https://doi.org/10.1097/mpg.0000000000000666
[11.] Mayo Clinic. Celiac Disease - Symptoms and Causes. Mayo Clinic. Published September 12, 2023. https://www.mayoclinic.org/diseases-conditions/celiac-disease/symptoms-causes/syc-20352220
[12.] Mefleh M, Motzo R, Samson M, Morel MH, Giunta F. N Partitioning between Gluten Fractions in a Set of Italian Durum Wheat Cultivars: Role of the Grain N Content. 2020;9(11):1684-1684. doi:https://doi.org/10.3390/foods9111684
[13.] Mitea C, Salentijn EMJ, van Veelen P, et al. A Universal Approach to Eliminate Antigenic Properties of Alpha-Gliadin Peptides in Celiac Disease. Uversky VN, ed. PLoS ONE. 2010;5(12):e15637. doi:https://doi.org/10.1371/journal.pone.0015637
[14.] Rupa Health. Array 14 Sample Report.pdf. Google Docs. Accessed June 21, 2024. https://drive.google.com/file/d/1mfK-jPiiFGtgYlMWVkx7vYPRigkvCHQs/view
[15.] Sayed SK, Imam HM, Mahran AM, Refaiy AM. Diagnostic utility of deamidated gliadin peptide antibody in celiac disease compared to anti-tissue transglutaminase and IgA- endomysium antibodies. Egypt J Immunol. 2012;19(2):41-52. PMID: 23885406.
[16.] ten Dam M, Van De Wal Y, Mearin ML, Kooy Y, Peña S, Drijfhout JW, Koning F, Van Tol M. Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin. Clin Exp Immunol. 1998 Nov;114(2):189-95. doi: 10.1046/j.1365-2249.1998.00722.x. PMID: 9822275; PMCID: PMC1905116.
[17.] Unsworth DJ, Kieffer M, Holborow EJ, Coombs RR, Walker-Smith JA. IgA anti-gliadin antibodies in coeliac disease. Clin Exp Immunol. 1981 Nov;46(2):286-93. PMID: 7039883; PMCID: PMC1536402.
[18.] Vojdani A, Vojdani E. Gluten and non-gluten proteins of wheat as target antigens in autism, Crohn’s and celiac disease. Journal of Cereal Science. 2017;75:252-260. doi:https://doi.org/10.1016/j.jcs.2017.04.010
[19.] Vojdani A. For the Assessment of Intestinal Permeability, Size Matters. Alternative Therapies. 2013;19(1):12-24.
[20.] Vojdani A, Tarash I. Cross-Reaction between Gliadin and Different Food and Tissue Antigens. Food and Nutrition Sciences. 2013;04(01):20-32. doi:https://doi.org/10.4236/fns.2013.41005
[21.] Akdis, C.A. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?. Nat Rev Immunol 21, 739–751 (2021). https://doi.org/10.1038/s41577-021-00538-7
[22.] Lindberg E, Magnusson KE, Tysk C, Järnerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut. 1992 Jul;33(7):909-13. doi: 10.1136/gut.33.7.909. PMID: 1644330; PMCID: PMC1379403.